Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on clinical data releases, financial results, and material corporate agreements for this commercial-stage biopharmaceutical company focused on targeted cancer therapies.
Day One uses Form 8-K to report material events such as updated three-year data from the pivotal FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma, financial results for specific quarters, and changes to corporate presentations. For example, an 8-K dated November 24, 2025 describes FIREFLY-1 efficacy and safety outcomes, while other 8-Ks attach press releases and slide decks summarizing OJEMDA net product revenue, license revenue, operating expenses, and cash balances.
Filings also document transactional and corporate actions. An 8-K filed in November 2025 outlines the Agreement and Plan of Merger through which Day One agreed to acquire Mersana Therapeutics via a tender offer and subsequent merger, including the structure of cash consideration and contingent value rights. Another 8-K describes an option repricing approved by the board of directors, providing detail on how stock options for certain directors and employees are adjusted and conditioned on continued service.
Through these SEC documents, readers can examine how Day One reports clinical trial outcomes, such as response rates and treatment-free intervals from FIREFLY-1, as well as how it communicates financial performance and corporate governance decisions. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight key points, helping users quickly understand the context of each report while preserving access to the full underlying documents.
In addition to 8-Ks, investors may use this page as a starting point to locate Day One’s annual and quarterly reports, which provide broader overviews of its oncology pipeline, including OJEMDA, DAY301, and Emi-Le, and its status as a Nasdaq Global Select Market registrant under the symbol DAWN.
Day One Biopharmaceuticals describes a fast‑expanding oncology business centered on OJEMDA (tovorafenib), approved in the United States for relapsed or refractory pediatric low‑grade glioma with BRAF alterations. Approval was supported by FIREFLY‑1, where overall response rates were about 51–53% with mostly Grade 1–2 side effects.
The company is running the pivotal FIREFLY‑2 Phase 3 front‑line trial in pLGG and multiple investigator‑initiated studies. Outside the United States, Day One licensed commercialization rights for tovorafenib to Ipsen, receiving a $70.8 million upfront payment plus a $40.0 million equity investment and eligibility for up to about $375.0 million in milestones and tiered double‑digit royalties.
Day One is broadening its pipeline with two antibody‑drug conjugates. It acquired Mersana Therapeutics, adding Emi‑Le (XMT‑1660), a B7‑H4‑targeted ADC in Phase 1 with early activity in adenoid cystic carcinoma. Through the MabCare license, it obtained DAY301, a PTK7‑targeted ADC now in a Phase 1a/b dose‑escalation study after a $55.0 million upfront payment and substantial milestone and royalty commitments.
Day One Biopharmaceuticals reported strong growth for 2025, driven by OJEMDA. Net product revenue reached
The company reaffirmed 2026 U.S. OJEMDA net product revenue guidance of
Day One Biopharmaceuticals’ Chief Commercial Officer Lauren Merendino reported several equity transactions. On February 17, 2026, she sold 5,814 shares of common stock in an open-market sale at a weighted average price of $11.6009 per share, solely to cover tax liabilities from RSU settlements.
On February 15, 2026, multiple Restricted Stock Units converted into common stock at no cost, increasing her direct holdings. Footnotes state each RSU converts into one common share, does not expire, and vests in scheduled quarterly installments contingent on continued service.
Day One Biopharmaceuticals general counsel and secretary Adam Dubow reported an open-market sale of 6,395 shares of common stock at a weighted-average price of $11.6009, undertaken solely to cover his tax liability from the settlement of restricted stock units.
On February 15, several restricted stock unit (RSU) awards were settled into common stock at no cash cost, with each RSU delivering one share upon vesting. After these transactions, Dubow directly held 72,694 shares of common stock. The RSUs vest over time in quarterly installments, subject to his continued service.
Day One Biopharmaceuticals COO and CFO Charles N. York II reported a mix of stock sales and equity award settlements. He sold 6,065 shares of Common Stock in an open-market transaction at a weighted average price of $11.6009 per share. A footnote states this sale was solely to cover his tax liability arising from restricted stock unit (RSU) settlements.
On the same general timeline, he exercised and settled multiple RSU awards, each representing a right to receive one share of Common Stock for no cash consideration. The RSUs vest quarterly in 1/16th increments on February 15, May 15, August 15 and November 15, as long as he continues providing service to the company.
Day One Biopharmaceuticals, Inc. CEO Jeremy Bender reported a mix of RSU settlements and a tax-related share sale. On February 17, he sold 15,459 shares of common stock in an open-market transaction at a weighted average price of $11.6009 per share to cover tax liabilities from recently settled restricted stock units (RSUs).
Around February 15, multiple RSU awards were converted into common shares at no cash cost, reflecting equity compensation vesting. After these transactions, Bender directly held 204,603 shares of common stock, and additional shares are held indirectly through several Bender family and grantor retained annuity trusts. The RSUs vest in equal quarterly installments, so further scheduled vesting may occur if service continues.
Day One Biopharmaceuticals’ Head of Research and Development, Michael Vasconcelles, reported RSU vesting and a related share sale. On February 15, he acquired 7,125 shares of common stock at $0 per share through the settlement of Restricted Stock Units, each RSU converting into one common share.
On February 17, he conducted an open‑market sale of 2,728 common shares at a weighted average price of $11.6009 per share. The company notes that this sale was made solely to cover his tax liability arising from the RSU settlement and that the sale price reflects block trades executed within a range of $11.195 to $11.8508. After these transactions, he continued to hold common shares directly and retained a substantial RSU balance that vests quarterly, subject to continued service.
A holder of DAWN common stock has filed a notice of proposed sale under Rule 144. The filing covers 15,459 common shares, to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $179,338.31.
The shares are part of a larger base of 102,675,502 shares outstanding and were acquired as restricted stock from the issuer on 02/15/2026. The planned sale date is approximately 02/17/2026 on the NASDAQ exchange.
A holder of DAWN common stock filed a notice to sell up to 6,065 shares under Rule 144. The shares have an indicated aggregate market value of $70,359.46 and are planned to be sold on NASDAQ, using Morgan Stanley Smith Barney LLC Executive Financial Services as broker.
The securities were acquired from the issuer as restricted stock on 02/15/2026, and full payment was listed as not applicable. The notice reports 102,675,502 shares of this class outstanding, providing context for the relative size of the planned sale.
A holder of DAWN common stock filed a Rule 144 notice to sell up to 5,814 shares on NASDAQ through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of
The shares to be sold were acquired on 02/15/2026 as restricted stock from the issuer, with the nature of payment described as not applicable. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.